Ó³»­´«Ã½

Our Cellular Pharmacology team leverages a comprehensive suite of cutting-edge technologies to dissect the fundamental biology of human health and disease. Our expertise spans target identification and validation, elucidating mechanisms of action, cellular pharmacology, biomarker identification, and advanced (high-throughput) screening methodologies.

We work with both internal and external partners, offering invaluable support throughout the drug discovery pipeline. From early-stage target validation to preclinical study development, we provide critical biological insights to drive scientists' research forward, including expert guidance on the strength of researchers' validation data, identification of potential gaps, and the collaborative design and execution of additional genetic and pharmacological validation studies.

Hit Identification Through Lead Optimization Studies

For hit identification, we specialize in developing and implementing tailored cell-based assays optimized for scalable (high-throughput) compound assessment. We also provide advice, design and execution of orthogonal cellular assays for rigorous hit validation, lead identification, and optimization. To confirm target engagement of promising candidates, we offer expertise in implementing cellular thermal shift assays (CETSA), utilizing both direct intracellular measurements (using HiBiT technology) and cellular lysates.

Preclinical Studies

As projects advance, we provide valuable pharmacological insights to inform early animal studies, with a focus on defining exposure-response relationships and potential liabilities in vivo. We also collaborate with leading researchers to investigate drug activity in disease-relevant mouse models and leverage our network of CROs to assess pharmacokinetic/pharmacodynamic (PK/PD) relationships and absorption, distribution, metabolism, and excretion (ADME) properties of lead molecules.